Impact of antimicrobial strategies on clinical outcomes of adults with septic shock and community-onset Enterobacteriaceae bacteremia: De-escalation is beneficial

Diagnostic Microbiology and Infectious Disease

Volumn 82, Issue 2, 2015, Pages 158-164

  Lee, Ching Chi ^a   Lee, Nan Yao ^a   Chen, Po Lin ^a   Hong, Ming Yuan ^a   Chan, Tsung Yu ^a   Chi, Chih Hsien ^a,b   Ko, Wen Chien ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Community onset bacteremia; De escalation antimicrobial therapy; Enterobacteriaceae; Septic shock

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLAVULANIC ACID; ERTAPENEM; LEVOFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT INFORMATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVAL TIME; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; ENTEROBACTERIACEAE INFECTIONS; MIDDLE AGED; SHOCK, SEPTIC; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84929050473     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.03.004     Document Type: Article

References (30)

1. Alvarez-Lerma F., Alvarez B., Luque P., Ruiz F., Dominguez-Roldan J.M., Quintana E., et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006, 10(3):R78.
2. Bates D.W., Pruess K.E., Lee T.H. How bad are bacteremia and sepsis? Outcomes in a cohort with suspected bacteremia. Arch Intern Med 1995, 155(6):593-598.
3. Chen H.C., Lin W.L., Lin C.C., Hsieh W.H., Hsieh C.H., Wu M.H., et al. Outcome of inadequate empirical antibiotic therapy in emergency department patients with community-onset bloodstream infections. J Antimicrob Chemother 2013, 68(4):947-953.
4. Cheong H.S., Kang C.I., Wi Y.M., Kim E.S., Lee J.S., Ko K.S., et al. Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia. Am J Med 2008, 121(8):709-714.
5. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; eighteen informational supplement. Supplement. CLSI document M100-S18 2008, CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M07-A9 2012, CLSI, Wayne, PA. 9th ed.
7. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. Supplement. CLSI document M100-S24 2014, CLSI, Wayne, PA.
8. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34(1):17-60.
9. Garnacho-Montero J., Gutierrez-Pizarraya A., Escoresca-Ortega A., Corcia-Palomo Y., Fernandez-Delgado E., Herrera-Melero I., et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014, 40(1):32-40.
10. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115(7):529-535.
11. Haug J.B., Harthug S., Kalager T., Digranes A., Solberg C.O. Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome. Clin Infect Dis 1994, 19(2):246-256.
12. Heenen S., Jacobs F., Vincent J.L. Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often?. Crit Care Med 2012, 40(5):1404-1409.
13. Hoffken G., Niederman M.S. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002, 122(6):2183-2196.
14. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118(1):146-155.
15. Ispahani P., Pearson N.J., Greenwood D. An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. Q J Med 1987, 63(2):427-440.
16. Kollef M.H., Morrow L.E., Niederman M.S., Leeper K.V., Anzueto A., Benz-Scott L., et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006, 129(5):1210-1218.
17. Lautenbach E., Patel J.B., Bilker W.B., Edelstein P.H., Fishman N.O. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001, 32(8):1162-1171.
18. Lee C.I., Lee N.Y., Yan J.J., Lee H.C., Ko N.Y., Chang C.M., et al. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia. J Microbiol Immunol Infect 2009, 42(2):303-309.
19. Lee C.C., Lee C.H., Chuang M.C., Hong M.Y., Hsu H.C., Ko W.C. Impact of inappropriate empirical antibiotic therapy on outcome of bacteremic adults visiting the ED. Am J Emerg Med 2012, 30(8):1447-1456.
20. Leibovici L., Greenshtain S., Cohen O., Mor F., Wysenbeek A.J. Bacteremia in febrile patients. A clinical model for diagnosis. Arch Intern Med 1991, 151:1801-1806.
21. Leibovici L., Samra Z., Konisberger H., Kalter-Leibovici O., Pitlik S.D., Drucker M. Bacteremia in adult diabetic patients. Diabetes Care 1991, 14(1):89-94.
22. Leibovici L., Shraga I., Drucker M., Konigsberger H., Samra Z., Pitlik S.D. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998, 244(5):379-386.
23. Leone M., Bourgoin A., Cambon S., Dubuc M., Albanese J., Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003, 31(2):462-467.
24. McCabe W.R. Gram-negative bacteremia. Adv Intern Med 1974, 19:135-158.
25. Niederman M.S. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001, 29(4 Suppl.):N114-N120.
26. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004, 140(1):26-32.
27. Salomao R., Castelo Filho A., Pignatari A.C., Wey S.B. Nosocomial and community acquired bacteremia: variables associated with outcomes. Rev Paul Med 1993, 111(6):456-461.
28. Schellevis F.G., van der Velden J., van de Lisdonk E., van Eijk J.T., van Weel C. Comorbidity of chronic diseases in general practice. J Clin Epidemiol 1993, 46(5):469-473.
29. Silva B.N., Andriolo R.B., Atallah A.N., Salomao R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev 2013, 3:CD007934.
30. Yates R.R. New intervention strategies for reducing antibiotic resistance. Chest 1999, 115(3 Suppl):24S-27S.